Hansa Biopharma – Deep Dive: Gene Therapy
Friday November 5, 2021 at 11:00 am, you have the opportunity to meet with Hansa Biopharma’s Global Franchise Lead for Gene Therapy, Dr. Lena Windstedt, PhD
Lena Winstedt will present Hansa’s Gene Therapy Franchise as an emerging opportunity to address issues around pre-existing antibodies to AAV-based gene therapies. The session will be held in English and be followed by a Q&A session, where you have the possibility to ask questions.
Last year, Hansa Biopharma announced an exclusive partnership in Gene Therapy with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment in Duchenne Muscular Dystrophy (DMD) and Limb-Girdle Muscular Dystrophy (LGMD). As part of the agreement Hansa is eligible for up to USD 400m in milestone payments plus sales and royalties enabled by imlifidase.
Beyond gene therapy Hansa Biopharma is probably best known for its antibody-cleaving enzymes platform in relation to kidney transplantation, where the company received conditional approval in Europe last year to enable kidney transplantation in highly sensitized patients, who are incompatible to a deceased donor.
Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm